OBI Pharma, Inc. (TPEX:4174)
Taiwan · Delayed Price · Currency is TWD 26.00
+1.05 (4.21%)
Sep 8, 2026, 1:30 PM CST
OBI Pharma Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,283 | 7,100 | 15,388 | 15,910 | 15,831 | 22,680 | |
Market Cap Growth | -54.27% | -53.86% | -3.28% | 0.50% | -30.20% | -13.48% |
Enterprise Value | 3,939 | 6,951 | 15,559 | 14,396 | 12,411 | 21,039 |
Last Close Price | 24.95 | 54.00 | 117.00 | 137.98 | 137.38 | 224.38 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | - | 106.36 | 106.36 | 106.36 | 106.36 | 106.36 |
PS Ratio | 62.89 | 121.22 | 245.51 | 382.92 | 3360.52 | 1208.19 |
PB Ratio | 1.50 | 2.61 | 3.19 | 3.21 | 2.58 | 5.86 |
P/TBV Ratio | 2.27 | 3.86 | 4.10 | 4.26 | 3.73 | 9.79 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 75.46 | 118.67 | 248.24 | 346.49 | 2634.54 | 1120.77 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.20 | 0.19 | 0.11 | 0.11 | 0.05 | 0.08 |
Net Debt / Equity Ratio | -0.02 | -0.25 | -0.55 | -0.45 | -0.73 | -0.61 |
Net Debt / EBITDA Ratio | 0.03 | 0.34 | 1.19 | 1.17 | 2.32 | 1.52 |
Net Debt / FCF Ratio | 0.03 | 0.33 | 1.35 | 1.27 | 2.39 | 1.81 |
Asset Turnover | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
Inventory Turnover | 5.75 | 5.90 | 5.18 | 4.80 | 2.85 | 5.24 |
Quick Ratio | 3.36 | 4.30 | 8.20 | 18.18 | 21.71 | 8.18 |
Current Ratio | 3.70 | 4.51 | 8.34 | 19.10 | 22.76 | 8.72 |
Return on Equity (ROE) | -61.67% | -59.82% | -51.01% | -22.83% | -37.96% | -39.45% |
Return on Assets (ROA) | -29.22% | -29.87% | -26.32% | -21.33% | -23.86% | -21.83% |
Return on Capital Employed (ROCE) | -66.60% | -70.60% | -45.20% | -38.40% | -33.10% | -41.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -46.48% | -28.91% | -15.01% | -6.58% | -10.19% | -6.75% |
FCF Yield | -47.16% | -29.07% | -12.65% | -11.03% | -11.84% | -5.76% |
Buyback Yield / Dilution | -5.05% | -12.56% | -1.99% | -3.12% | -11.65% | -0.18% |